Inventors Recognition Program
In the second half of FY 2014, NIAID recognized the following individuals for their contributions to the U.S. patents listed below (only current NIAID employees are shown):
United States patent 8,821,866 was issued on September 2, 2014, for “Methods of treating and preventing colitis involving IL-13 and NK-T cells.” NIAID inventors: Warren Strober, M.D., Ivan J. Fuss , M.D.
United States patent 8,921,071 was issued on December 30, 2014, for “Targeting poly-gamma-glutamic acid to treat Staphylococcus epidermidis and related infections.” NIAID inventors: Michael Otto, PhD.
United States patent 8,961,975 was issued on February 24, 2015, for “Monoclonal antibodies that neutralize anthrax toxins.” NIAID inventors: Zhaochun Chen, Ph.D., Stephen Leppla, Ph.D., Mahtab Moayeri.
United States patent 8,980,859 was issued on March 17, 2015, for “Aegyptin and uses thereof.” NIAID inventors: Jose M. C. Ribeiro, M.D., Ph.D., Ivo Francischetti, M.D., Ph.D., Eric Calvo, Ph.D.
United States patent 8,999,336 was issued on April 7, 2015, for “Monoclonal antibodies against orthopoxviruses.” NIAID inventors: Zhaochun Chen, Ph.D., Patricia Earl, Ph.D., Bernard Moss, M.D., Ph.D.
United States patent 9,012,618 was issued on April 21, 2015, for “Nucleic acids encoding modified Ebola virus glycoproteins with diminished cytotoxicity while retaining native antigenic structures.” NIAID inventor: Nancy Sullivan, Ph.D.
Recent Collaborative Agreements
NIAID and MedImmune/AstraZeneca signed a cooperative research and development agreement (CRADA) to study the development of live, attenuated vaccines for pandemic influenza. NIAID principal investigator: Kanta Subbarao, M.B.B.S., M.P.H.
NIAID and Amgen signed a materials CRADA (MCRADA) to analyze the ability of novel HIV immunogens to induce broadly neutralizing antibodies in Amgen, Inc.'s proprietary XenoMouse Model. NIAID principal investigator: John Mascola, M.D.
NIAID and University of Cambridge entered a research collaboration agreement (RCA) for the development of novel affinity ligands for development of alphavirus and influenza vaccines. NIAID principal investigator: Richard Schwartz, Ph.D.
NIAID and Sirigen Group Limited (acquired by Becton, Dickinson) signed a CRADA on the optimization of multicolor flow cytometry using Becton, Dickinson's cytometer, including the Ultra LSRII, and fluorescent dyes, including those from their Sirigen subsidiary. NIAID principal investigator: Mario Roederer, Ph.D.
NIAID and Merck & Co., Inc., signed an intramural clinical CRADA on the development of a prime-boost vaccination strategy for the control of dengue using NIAID's tetravalent live, attenuated dengue virus TV-003 and/or TV-005 vaccine formulation and Merck's tetravalent subunit V180 vaccine formulation. NIAID principal investigator: Kanta Subbarao, M.B.B.S., M.P.H.
NIAID and the University of Cambridge entered an RCA on the development of novel affinity ligands for development of alphavirus and influenza vaccines. NIAID principal investigator: Richard Schwartz, Ph.D.
NIAID and Sanofi US Services Inc. signed a CRADA on the development of novel bi- or multi-specific antibodies for treatment or prevention of HIV-1 infection based on NIAID antibodies and Sanofi's proprietary multi-specific antibody technology. NIAID principal investigator: Richard Koup, M.D.
NIAID and Kansas State University entered an RCA to extrapolate techniques and methodologies developed for porcine respiratory and reproductive syndrome virus (PRRSV) to simian hemorrhagic fever virus (SHFV). NIAID principal investigator: Peter Jahrling, Ph.D.
NIAID and Millennium Pharmaceuticals, Inc., entered an MCRADA to study the role of nucleotide-oligomerization receptors in Toxoplasma gondii and related pathogen infection. NIAID principal investigator: Alan Sher, Ph.D.
NIAID and MacroGenics, Inc., entered into an RCA on the elimination of HIV reservoirs using novel antibody-like compounds that target HIV Env. NIAID principal investigator: Tae-Wook Chun, Ph.D.
NIAID and the Geisel School of Medicine at Dartmouth College entered an RCA to elucidate molecular mechanisms of virus entry and antibody-mediated neutralization of filoviruses, with the ultimate goal of developing vaccines and prophylactic antibodies. NIAID principal investigator: Nancy Sullivan, Ph.D.
NIAID and BioAegis Therapeutics, Inc., entered an external RCA to study the role of gelsolin in human diseases with significant inflammatory and infectious complications. NIAID principal investigator: Kol Zarember, Ph.D.
NIAID and the University of California-San Francisco entered an RCA to study structural and mechanistic aspects of the HIV envelope protein. NIAID principal investigator: Peter Kwong, Ph.D.
NIAID and BIOCARTIS entered an RCA to research an Ebola test kit. NIAID principal investigator: Peter Jahrling, Ph.D.
Last Updated January 23, 2015